Biotechnology News and Research

RSS

Bioengineering delivers innovative solutions to diagnose and repair TBI

Bioengineering -- the application of engineering principles to understand and treat medical conditions -- is delivering innovative solutions for diagnosing and repairing damage to the brain caused by a traumatic injury.

23 Nov 2011

Pfizer enters definitive agreement to acquire Excaliard

Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.

22 Nov 2011

PAREXEL implements fMRI technology in early phase CNS drug development

PAREXEL International, a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

From Parexel 22 Nov 2011

Scientists search for main culprit behind Sj-gren's syndrome

Researchers want to find the main culprit behind the dry, irritated eyes, mouth, throat, skin, nose and more afflicting 1-3 percent of the population.

22 Nov 2011

SAFC commences process validation activities for Oncolytics' REOLYSIN

Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.

21 Nov 2011

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

ZIOPHARM Oncology, Inc. announced today the publication of a darinaparsin (Zinapar or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science.

21 Nov 2011

BioSante listed on NASDAQ Biotechnology Index

BioSante Pharmaceuticals, Inc. today announced that it has been added to the NASDAQ Biotechnology Index, effective prior to the stock market open today, November 21, 2011.

21 Nov 2011

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Exelixis, Inc. today announced the initiation of an investigator-sponsored trial of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.

21 Nov 2011

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

21 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

ShangPharma third quarter net revenues increase 24.7% to $28.8 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the quarter ended September 30, 2011.

21 Nov 2011

$GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation$

GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation

GE Healthcare, the healthcare business of GE and Neste Jacobs, a leading global expert in plasma fractionation plant engineering design and construction, announced today that the companies have formed a strategic alliance to assist countries worldwide to become self-sufficient in the manufacture of blood plasma products.

21 Nov 2011

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.

21 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Almac, a leading provider of contract services to the global pharmaceutical and biotech industries, responded earlier this year to an urgent request from their client partner, Alexion Pharmaceuticals, Inc., a global biotechnology company, for packaging and distribution of Soliris (eculizumab) for patients with STEC-HUS during the E. coli outbreak in Germany earlier this year.

21 Nov 2011

Wake Forest Baptist, VA partner to advance treatment of PTSD and TBI

Researchers at Wake Forest Baptist Medical Center and the U.S. Department of Veterans Affairs (VA) are teaming up for a research project aimed at advancing the treatment of military personnel suffering from post-traumatic stress disorder (PTSD) and traumatic brain injury.

19 Nov 2011

Biotechnology News and Research

Bioengineering delivers innovative solutions to diagnose and repair TBI

Pfizer enters definitive agreement to acquire Excaliard

PAREXEL implements fMRI technology in early phase CNS drug development

Scientists search for main culprit behind Sj-gren's syndrome

SAFC commences process validation activities for Oncolytics' REOLYSIN

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

BioSante listed on NASDAQ Biotechnology Index

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

ShangPharma third quarter net revenues increase 24.7% to $28.8 million

GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Wake Forest Baptist, VA partner to advance treatment of PTSD and TBI

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Tikcro reports net loss of $1.0 million for third quarter 2011

InDevR introduces ampliPHOX system for microbiological analysis

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News